Daniel Kavanagh, PhD, RAC
Senior Scientific Advisor, Gene Therapy, Vaccines & Biologics , WCG
Biography
Daniel Kavanagh, PhD, RAC, is the senior scientific advisor of gene therapy, vaccines, and biologics at WCG. Prior to joining WCG, he was assistant professor of medicine and Institutional Biosafety Committee vice chair at Harvard Medical School, and assistant immunologist at the Massachusetts General Hospital. He was also co-chair of a Phase 1 clinical trial of a therapeutic mRNA vaccine. He is certified in US Regulatory Affairs (RAC) by the Regulatory Affairs Professional Society.
Latest insights by Daniel
							
			Series: WCG Trends & Insights 2025
			
	
		
		Elevating Site Preparedness: Trends and Strategies for 2025
Blog Posts
							
			Precision Oncology & Biomarker Driven Clinical Trials
			
	
		
		Advancing Precision Medicine: Harnessing Molecular Biomarkers for Oncology Clinical Trials
Blog Posts
							
			Clinical Trial Safety
			
	
		
		Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease
Blog Posts
							
			Biosafety
			
	
		
		Ask the Experts: Submitting Separate Information Between Studies and Sites
Blog Posts
							
			Series: WCG Talks Trials
			
	
		
		The Ethical and Safety Considerations of Accelerating Oncology Trials
Podcasts
							
			Series: WCG Trends & Insights for 2024
			
	
		
		The Decentralization of Vaccines in 2024 and Beyond
Blog Posts
							
			Cell & Gene Therapy
			
	
		
		Key Takeaways From FDA’s New Draft Guidance, “Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial”
Blog Posts
							
			Cell & Gene Therapy
			
	
		
		Four Key Elements You Need to Know About the Role of IBCs in Gene Therapy Trials
Blog Posts
							
			Cell & Gene Therapy
			
	
		
		As a sponsor, does my HGT clinical trial require IBC approval at all sites?
Blog Posts
							
			Cell & Gene Therapy